作者
Alexandros Rampotas,Luke Carter‐Brzezinski,Tim C. P. Somervaille,James Forryan,Fotios Panitsas,Claire Harrison,Ruth Witherall,Andrew J. Innes,Louise Wallis,Naumann M. Butt,Bethan Psaila,Adam J. Mead,Matthew Carter,Anna L. Godfrey,Heather Laing,Mamta Garg,Sebastian Francis,Joanne Ewing,Chun Huat Teh,Hannah Bibi Cowen,Peter Dyer,Conall McConville,Frances Wadelin,Ali Sahra,Andrew McGregor,Elizabeth Kulakov,Donal P. McLornan,Jonathan Lambert
摘要
Abstract Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.
爱静静
嗯哼
朝阳区李知恩
寻道图强
现代青枫
彭于彦祖
cannon8
Leonardi
面向杂志编论文
于芋菊
Jenny
不配.
从容芮
8R60d8
浅尝离白
浅惜
宜醉宜游宜睡
pcr163
kento
iNk
皖公网安备34019202002308
